Results 61 to 70 of about 1,330 (154)

Engineering and evaluation of FXa bypassing agents that restore hemostasis following Apixaban associated bleeding

Nature Communications
Direct oral anticoagulants (DOACs) targeting activated factor Xa (FXa) are used to prevent or treat thromboembolic disorders. DOACs reversibly bind to FXa and inhibit its enzymatic activity.
Wojciech Jankowski, Stepan S. Surov, Nancy E. Hernandez, Atul Rawal, Marcos Battistel, Daron Freedberg, Mikhail V. Ovanesov, Zuben E. Sauna   +7 more
doaj   +1 more source

Poster Sessions

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

JCS/JHRS 2024 Guideline Focused Update on Management of Cardiac Arrhythmias

Journal of Arrhythmia, Volume 41, Issue 3, June 2025.
Yu‐ki Iwasaki, Takashi Noda, Masaharu Akao, Tadashi Fujino, Teruyuki Hirano, Koichi Inoue, Kengo Kusano, Toshiyuki Nagai, Kazuhiro Satomi, Tetsuji Shinohara, Kyoko Soejima, Yohei Sotomi, Shinya Suzuki, Teiichi Yamane, Tsukasa Kamakura, Hiroyuki Kato, Arimi Katsume, Yusuke Kondo, Kenji Kuroki, Hisaki Makimoto, Hiroshige Murata, Takafumi Oka, Nobuaki Tanaka, Nobuhiko Ueda, Hiro Yamasaki, Seigo Yamashita, Ryobun Yasuoka, Kenji Yodogawa, Kazutaka Aonuma, Takanori Ikeda, Toru Minamino, Hideo Mitamura, Akihiko Nogami, Ken Okumura, Hiroshi Tada, Takashi Kurita, Wataru Shimizu, on behalf of the Japanese Circulation Society and Japanese Heart Rhythm Society Joint Working Group   +37 more
wiley   +1 more source

SPECIFIC ANTIDOTES TO NEW ORAL ANTICOAGULANTS

Атеротромбоз, 2016
Safety profiles of the novel oral anticoagulants (NOAC) (rivaroxaban, apixaban, edoxaban,  dabigatran) are better than that of warfarin. However, the risk (including lifethreatening) of bleeding  is no less than 2.3–3.1% per year.
O. O. Shakhmatova
doaj   +1 more source

Case Report: Isolated homonymous hemianopia after reversal of anticoagulation with andexanet alfa

Frontiers in Neurology
PurposeClinical scoring systems have been developed (e.g., CHA2DS2-VASc and HAS-BLED) to aid in the perioperative management of anticoagulation therapy.
Paria Malekahmadi, Dina Abdelsalam, Safa Ibrahim, Andrew Go Lee   +3 more
doaj   +1 more source

Andexanet Alfa and its Clinical Application [PDF]

Heart International, 2020
Fauve A, Noordergraaf, Marco, Alings
openaire   +2 more sources

Impact of code stroke on door-to-andexanet administration time for factor Xa inhibitor-associated intracranial hemorrhage: a single-center retrospective study

Frontiers in Neurology
BackgroundAdministration of andexanet alfa has shown to achieve hemostatic efficacy in factor Xa inhibitor (FXai)-associated intracranial hemorrhage (ICrH). Code stroke (CS), implemented through the visual task management application Task Calc.
Koji Tanaka, Eri Imazu, Takuma Ishihara, Junpei Koge, Tetsuya Hashimoto, Kazuyasu Matsumura, Eiji Fujiwara, Kenichiro Suyama, Jun Muto, Motoharu Hayakawa, Ayuko Yasuda, Ichiro Nakahara, Hiroshi Koyama, Jun-ichi Kira, Jun-ichi Kira, Yuichi Hirose, Shoji Matsumoto   +16 more
doaj   +1 more source

Reversing factor Xa inhibitors – clinical utility of andexanet alfa

Journal of Blood Medicine, 2017
Scott Kaatz,1 Hardik Bhansali,1 Joseph Gibbs,2 Robert Lavender,3 Charles E Mahan,4 David G Paje5 1Division of Hospital Medicine, 2Department of Internal Medicine, Henry Ford Hospital, Detroit, MI, 3Division of General Internal Medicine, University of ...
Kaatz S, Bhansali H, Gibbs J, Lavender R, Mahan CE, Paje DG   +5 more
doaj  

Specific reversal agents for direct oral anticoagulants in neurosurgical emergencies – a systematic review

Research and Practice in Thrombosis and Haemostasis
Background: Direct oral anticoagulants (DOACs) are widely used but pose significant challenges in emergency neurosurgical settings. Idarucizumab and andexanet alfa are approved reversal agents, yet their effectiveness and safety in neurosurgical ...
Laura Zeller, Jonas Rohr, Giovanna Brandi, Christoph Globas, Alexander Kaserer, Matthias Greutmann, Tilman Schubert, Jan-Dirk Studt, Katharina Geiling, Luca Regli, Menno R. Germans   +10 more
doaj   +1 more source

Reversal of direct oral anticoagulants

Vascular Health and Risk Management, 2017
Mosaad Almegren Department of Medicine, Al Imam Mohammad Ibn Saud Islamic University, Riyadh, Kingdom of Saudi Arabia Abstract: Reversal agents for direct oral anticoagulants (DOACs), including factor X inhibitors and direct thrombin inhibitors, are a ...
Almegren M
doaj